Skip to main content

Table 1 Demographic, clinical, genetic and radiographic characteristics of African American participants with RA and healthy controls from the CLEAR registry.

From: Dense Genotyping of Immune-Related Regions Identifies Loci for Rheumatoid Arthritis Risk and Damage in African Americans

  Cases Controls
Baseline characteristics CLEAR I N = 233 CLEAR II N = 360 CLEAR I N = 139 CLEAR II N = 265
Age in years, mean (SE) 50.0 (13.0) 56.0 (11.8) 48.1 (12.4) 57.3 (8.7)
Sex (female), % 82.7 85.0 75.5 72.0
Disease duration in months, mean (SE) 12.9 (7.1) 114.0 (119.2) - -
Body mass index, mean (SE) 31.4 (7.8) - 31.7 (7.6) -
Global European admixture estimate, mean (SE) 0.17 (0.09) 0.16 (0.10) 0.16 (0.09) 0.17 (0.10)
Number of tender joints, median (IQR 25–75) 4.0 (1.0–12.0) 4.0 (1.0–9.5) - -
Number of swollen joints, median (IQR 25–75) 3.0 (1.0–7.0) 4.0 (1.0–10.0) - -
Medications     
Biologics ever used (%) 4.4 - 19.5 -
Other DMARDs (%) 81.4 - 87.1 -
Methotrexate, current use (%) 63.9 60.3 - -
Radiographic score, mean (SE)     
Joint-erosion score 1.6 (4.3) 10.7 (18.5)   
Joint-narrowing score 2.1 (5.7) 18.1 (27.7)   
Total score 3.7 (9.4) 28.8 (44.1)   
  1. SE: standard error; IQR: interquartile range; DMARD: disease-modifying anti-rheumatic drug.